Avacta Group PLC has appointed Peel Hunt LLP as its Nominated Adviser and sole broker. The company, focused on developing targeted oncology drugs and diagnostics, aims to improve healthcare outcomes. Avacta has two divisions: a clinical stage oncology biotech division and a diagnostics division. The company utilizes two proprietary platforms, pre|CISION™ and Affimer®, with the pre|CISION™ platform specifically targeting fibroblast activation protein (FAP) highly upregulated in most solid tumors. The lead pre|CISION™ program AVA6000, a peptide drug conjugate form of doxorubicin, is currently in Phase 1 studies and has shown promising results in terms of safety, tolerability, and preliminary signs of clinical activity. For further information, individuals can contact Avacta Group plc or Peel Hunt LLP.